Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong · Delayed Price · Currency is HKD

52.05

+1.65 (3.27%)

Sep 30, 2026, 4:08 PM HKT

Market Cap	9.83B -25.1%
Revenue (ttm)	246.16M
Net Income	-308.20M
EPS	-1.59
Shares Out	195.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	698,300
Open	50.65
Previous Close	50.40
Day's Range	50.15 - 52.35
52-Week Range	44.72 - 97.50
Beta	n/a
Analysts	Strong Buy
Price Target	105.54 (+102.77%)
Est. Earnings	Dec 1, 2026

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity. In addition, it develops LeadsBody platform,... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 259

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 9887

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Summary

According to 5 analysts, the average rating for 9887 stock is "Strong Buy." The 12-month stock price target is $105.54, which is an increase of 102.77% from the latest price.

Price Target

$105.54

(102.77% upside)

Analyst Consensus: Strong Buy

Stock Forecasts